Shopping Cart 0
Cart Subtotal
USD 0

Atrial Fibrillation-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Atrial Fibrillation-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation-Pipeline Review, H1 2017, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 2, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Atrial Fibrillation-Overview

Atrial Fibrillation-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Atrial Fibrillation-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Atrial Fibrillation-Companies Involved in Therapeutics Development

Acesion Pharma Aps

Allosteros Therapeutics Inc

ARCA biopharma Inc

Armetheon Inc

AstraZeneca Plc

Bristol-Myers Squibb Company

Cardiome Pharma Corp

Daiichi Sankyo Company Ltd

Dong-A Socio Holdings Co Ltd

Gilead Sciences Inc

InCarda Therapeutics Inc

Merck & Co Inc

Nissan Chemical Industries Ltd

Nyken BV

OMEICOS Therapeutics GmbH

Verseon Corp

Atrial Fibrillation-Drug Profiles

AFC-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-919373-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bucindolol hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budiodarone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flecainide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Atrial Fibrillation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-967-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1832-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIP-151-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYK-1112-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-28-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Atrial Fibrillation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Kv1.5 for Atrial Fibrillation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block GIRK for Atrial Fibrillation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-023725-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vernakalant hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Atrial Fibrillation-Dormant Projects

Atrial Fibrillation-Discontinued Products

Atrial Fibrillation-Product Development Milestones

Featured News & Press Releases

Feb 23, 2017: Daiichi Sankyo Europe Receives CHMP Positive Opinion for Roteas (edoxaban)

Feb 13, 2017: Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral anti-arrhythmic budiodarone

Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE

Nov 09, 2016: Once-Daily Anticoagulant LIXIANA (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism

Nov 07, 2016: Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

Oct 03, 2016: Daiichi Sankyo Announces Large-Scale Registry of Nonvalvular Atrial Fibrillation in the Elderly

Aug 30, 2016: ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion

Aug 30, 2016: Trial results for anticoagulants for cardioversion in AF patients published

Aug 24, 2016: Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban

Aug 24, 2016: Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016

May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study

May 02, 2016: New drug more effective in treating atrial fibrillation

Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation

Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session

Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Atrial Fibrillation, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Atrial Fibrillation, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Atrial Fibrillation-Pipeline by Acesion Pharma Aps, H1 2017

Atrial Fibrillation-Pipeline by Allosteros Therapeutics Inc, H1 2017

Atrial Fibrillation-Pipeline by ARCA biopharma Inc, H1 2017

Atrial Fibrillation-Pipeline by Armetheon Inc, H1 2017

Atrial Fibrillation-Pipeline by AstraZeneca Plc, H1 2017

Atrial Fibrillation-Pipeline by Bristol-Myers Squibb Company, H1 2017

Atrial Fibrillation-Pipeline by Cardiome Pharma Corp, H1 2017

Atrial Fibrillation-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Atrial Fibrillation-Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Atrial Fibrillation-Pipeline by Gilead Sciences Inc, H1 2017

Atrial Fibrillation-Pipeline by InCarda Therapeutics Inc, H1 2017

Atrial Fibrillation-Pipeline by Merck & Co Inc, H1 2017

Atrial Fibrillation-Pipeline by Nissan Chemical Industries Ltd, H1 2017

Atrial Fibrillation-Pipeline by Nyken BV, H1 2017

Atrial Fibrillation-Pipeline by OMEICOS Therapeutics GmbH, H1 2017

Atrial Fibrillation-Pipeline by Verseon Corp, H1 2017

Atrial Fibrillation-Dormant Projects, H1 2017

Atrial Fibrillation-Dormant Projects, H1 2017 (Contd..1), H1 2017

Atrial Fibrillation-Dormant Projects, H1 2017 (Contd..2), H1 2017

Atrial Fibrillation-Discontinued Products, H1 2017

Atrial Fibrillation-Discontinued Products, H1 2017 (Contd..1), H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Atrial Fibrillation Therapeutic Products under Development, Key Players in Atrial Fibrillation Therapeutics, Atrial Fibrillation Pipeline Overview, Atrial Fibrillation Pipeline, Atrial Fibrillation Pipeline Assessment


Companies

Acesion Pharma Aps, Allosteros Therapeutics Inc, ARCA biopharma Inc, Armetheon Inc, AstraZeneca Plc, Bristol-Myers Squibb Company, Cardiome Pharma Corp, Daiichi Sankyo Company Ltd, Dong-A Socio Holdings Co Ltd, Gilead Sciences Inc, InCarda Therapeutics Inc, Merck & Co Inc, Nissan Chemical Industries Ltd, Nyken BV, OMEICOS Therapeutics GmbH, Verseon Corp